Conference abstractPublished 26 Sep 2016
Lifitegrast and Other New Topical Medications for Dry Eye Disease
Toyos Clinic, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Over the last few years, more companies are spending more research dollars in developing new medications for dry eye disease (DED). We have completed and have several on going studies on different drops specifically designed for DED. Recently a medication, lifitegrast was approved. Lifitegrast is an anti-inflammatory drop that inhibits the binding of LFA-1 to ICAM-1 down-regulating the inflammation mediated by T lymphocytes. It is the only medication FDA approved for the signs and symptoms of DED. We will present FDA and our current research of this novel drop. We will also cover our work with platelet rich plasma eye drops, optimel, and oculocin. All work will include OSDI data, TBUT, and effects on lid margin disease.
Subjects
Ophthalmology & OptometryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectOphthalmology & Optometry
- BylineArticles whose byline prints “Rolando Toyos”